Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors

Jessica Sugianto, Venetia Sarode, Yan Peng

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Increased Ki-67 expression is associated with worse prognosis in patients with triple-negative breast carcinoma (TNBC); Ki-67 is widely used as a prognostic marker for TNBC patients. p16 and p53 are tumor suppressors. The status of p53 expression can divide TNBCs into 2 biologically distinct subgroups. The relationship of p16 expression with Ki-67 and its association with the status of p53 in TNBC patients have not been well characterized. In this study, we investigated p16 expression in 60 high-grade invasive TNBC cases and its relationship with Ki-67 in different groups of TNBCs and correlated p16 with Ki-67 in p53-positive and p53-negative subgroups. The tumors were immunolabeled for p16, Ki-67, and p53. Tissue microarrays were constructed with each tumor and adjacent normal breast tissue. Of the 60 tumors, 45 (75%) were found to have p16 expression. The triple-negative tumors had significantly higher p16 expression compared with paired normal ducts (P <.0001). Mean expression level of Ki-67 in p16-positive tumors was significantly higher than that in p16-negative tumors regardless of the status of p53 (P <.05). p16 expression positively correlated with Ki-67 (69.05% ± 7.23%) in the 22 p53-negative tumors (r = 0.739; P <.001). However, no correlation was found between p16 and Ki-67 (77.2% ± 3.83%) in the 38 p53-positive tumors (r = 0.157; P =.424). These findings suggest that p16 may play a role in the proliferation and aggressiveness of p53-negative TNBC and provide insights into the potential prognostic value of p16 as well as a better understanding of tumor biology related to the Rb/p16 pathway abnormalities.

Original languageEnglish (US)
Pages (from-to)802-809
Number of pages8
JournalHuman Pathology
Volume45
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Breast Neoplasms
Neoplasms
Breast

Keywords

  • Ki-67
  • p16
  • p53
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{bd0aaa4cb40146a9b6a099b198a9ad8f,
title = "Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors",
abstract = "Increased Ki-67 expression is associated with worse prognosis in patients with triple-negative breast carcinoma (TNBC); Ki-67 is widely used as a prognostic marker for TNBC patients. p16 and p53 are tumor suppressors. The status of p53 expression can divide TNBCs into 2 biologically distinct subgroups. The relationship of p16 expression with Ki-67 and its association with the status of p53 in TNBC patients have not been well characterized. In this study, we investigated p16 expression in 60 high-grade invasive TNBC cases and its relationship with Ki-67 in different groups of TNBCs and correlated p16 with Ki-67 in p53-positive and p53-negative subgroups. The tumors were immunolabeled for p16, Ki-67, and p53. Tissue microarrays were constructed with each tumor and adjacent normal breast tissue. Of the 60 tumors, 45 (75{\%}) were found to have p16 expression. The triple-negative tumors had significantly higher p16 expression compared with paired normal ducts (P <.0001). Mean expression level of Ki-67 in p16-positive tumors was significantly higher than that in p16-negative tumors regardless of the status of p53 (P <.05). p16 expression positively correlated with Ki-67 (69.05{\%} ± 7.23{\%}) in the 22 p53-negative tumors (r = 0.739; P <.001). However, no correlation was found between p16 and Ki-67 (77.2{\%} ± 3.83{\%}) in the 38 p53-positive tumors (r = 0.157; P =.424). These findings suggest that p16 may play a role in the proliferation and aggressiveness of p53-negative TNBC and provide insights into the potential prognostic value of p16 as well as a better understanding of tumor biology related to the Rb/p16 pathway abnormalities.",
keywords = "Ki-67, p16, p53, Triple-negative breast cancer",
author = "Jessica Sugianto and Venetia Sarode and Yan Peng",
year = "2014",
doi = "10.1016/j.humpath.2013.11.013",
language = "English (US)",
volume = "45",
pages = "802--809",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors

AU - Sugianto, Jessica

AU - Sarode, Venetia

AU - Peng, Yan

PY - 2014

Y1 - 2014

N2 - Increased Ki-67 expression is associated with worse prognosis in patients with triple-negative breast carcinoma (TNBC); Ki-67 is widely used as a prognostic marker for TNBC patients. p16 and p53 are tumor suppressors. The status of p53 expression can divide TNBCs into 2 biologically distinct subgroups. The relationship of p16 expression with Ki-67 and its association with the status of p53 in TNBC patients have not been well characterized. In this study, we investigated p16 expression in 60 high-grade invasive TNBC cases and its relationship with Ki-67 in different groups of TNBCs and correlated p16 with Ki-67 in p53-positive and p53-negative subgroups. The tumors were immunolabeled for p16, Ki-67, and p53. Tissue microarrays were constructed with each tumor and adjacent normal breast tissue. Of the 60 tumors, 45 (75%) were found to have p16 expression. The triple-negative tumors had significantly higher p16 expression compared with paired normal ducts (P <.0001). Mean expression level of Ki-67 in p16-positive tumors was significantly higher than that in p16-negative tumors regardless of the status of p53 (P <.05). p16 expression positively correlated with Ki-67 (69.05% ± 7.23%) in the 22 p53-negative tumors (r = 0.739; P <.001). However, no correlation was found between p16 and Ki-67 (77.2% ± 3.83%) in the 38 p53-positive tumors (r = 0.157; P =.424). These findings suggest that p16 may play a role in the proliferation and aggressiveness of p53-negative TNBC and provide insights into the potential prognostic value of p16 as well as a better understanding of tumor biology related to the Rb/p16 pathway abnormalities.

AB - Increased Ki-67 expression is associated with worse prognosis in patients with triple-negative breast carcinoma (TNBC); Ki-67 is widely used as a prognostic marker for TNBC patients. p16 and p53 are tumor suppressors. The status of p53 expression can divide TNBCs into 2 biologically distinct subgroups. The relationship of p16 expression with Ki-67 and its association with the status of p53 in TNBC patients have not been well characterized. In this study, we investigated p16 expression in 60 high-grade invasive TNBC cases and its relationship with Ki-67 in different groups of TNBCs and correlated p16 with Ki-67 in p53-positive and p53-negative subgroups. The tumors were immunolabeled for p16, Ki-67, and p53. Tissue microarrays were constructed with each tumor and adjacent normal breast tissue. Of the 60 tumors, 45 (75%) were found to have p16 expression. The triple-negative tumors had significantly higher p16 expression compared with paired normal ducts (P <.0001). Mean expression level of Ki-67 in p16-positive tumors was significantly higher than that in p16-negative tumors regardless of the status of p53 (P <.05). p16 expression positively correlated with Ki-67 (69.05% ± 7.23%) in the 22 p53-negative tumors (r = 0.739; P <.001). However, no correlation was found between p16 and Ki-67 (77.2% ± 3.83%) in the 38 p53-positive tumors (r = 0.157; P =.424). These findings suggest that p16 may play a role in the proliferation and aggressiveness of p53-negative TNBC and provide insights into the potential prognostic value of p16 as well as a better understanding of tumor biology related to the Rb/p16 pathway abnormalities.

KW - Ki-67

KW - p16

KW - p53

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84896548342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896548342&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2013.11.013

DO - 10.1016/j.humpath.2013.11.013

M3 - Article

C2 - 24560018

AN - SCOPUS:84896548342

VL - 45

SP - 802

EP - 809

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 4

ER -